Niederer Kraft Frey AG | View firm profile
Niederer Kraft Frey advised the shareholders of Institut für histologische und zytologische Diagnostik AG Aarau (IHZD) on the sale of IHZD to Affidea Group.
IHZD operates two laboratories in Aarau and Zurich, specialising in histopathology, molecular pathology and cytology diagnostics. By completing the sale to Affidea Group, the institute ensures its long-term sustainability, facilitates further growth, and creates new opportunities for its clients and employees as Affidea is Europe’s largest provider of diagnostic imaging, ambulatory care and cancer treatment. With the acquisition of IHZD, Affidea Switzerland is now in a position to offer a fully integrated oncological treatment pathway covering prevention, early detection, genetic testing, diagnosis, personalised treatment and post-treatment support.
The NKF team was led by Corporate/M&A partner Thomas Brönnimann, working with associates Manuel Hirlinger and Benedikt Hadorn, junior associate Matthias Zinniker (all Corporate/M&A), associate Stephanie Huchler (Employment) as well as senior associate Sven Kälin and associate Aleksa Stojadinovic (both Tax).